Literature DB >> 20146550

Opioid dependence treatment and guidelines.

Lance Nicholls1, Lisa Bragaw, Charles Ruetsch.   

Abstract

BACKGROUND: In response to the growing incidence of opioid dependence, guidelines have been created, and new treatments are being developed to assist physicians in treating dependence and withdrawal of opioids.
OBJECTIVE: To review treatment modalities and guidelines utilized in opioid dependence.
SUMMARY: Guidelines for the treatment of opioid dependence have been developed by organizations such as the American Society of Interventional Pain Physicians (ASIPP) and the American Psychiatric Association (APA). Current guidelines recommend comprehensive treatment with pharmacological agents such as methadone, buprenorphine, or buprenorphine combined with naloxone as well as psychosocial therapy. These guidelines stress the need for an integrated approach to treatment. Office-based opioid treatment is currently being utilized to treat opioid dependent patients in a physician's office setting with buprenorphine/naloxone replacement therapy as an alternative to entering patients into a methadone clinic. These office-based programs offer a breakthrough in access to care for dependent patients.
CONCLUSION: Physicians need to be aware of and adhere to currently accepted guidelines and recommendations for treating opioid dependent patients, including integrating psychosocial treatments and behavior modification strategies for optimal results. Clinicians must be educated on the new treatment modalities and regulations surrounding the use of these therapies. Copyright 2010, Academy of Managed Care Pharmacy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146550     DOI: 10.18553/jmcp.2010.16.s1-b.14

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  15 in total

1.  Psychological and physiological stress negatively impacts early engagement and retention of opioid-dependent individuals on methadone maintenance.

Authors:  Kellie M Jaremko; Robert C Sterling; Elisabeth J Van Bockstaele
Journal:  J Subst Abuse Treat       Date:  2014-08-29

2.  Impact of cannabis use during stabilization on methadone maintenance treatment.

Authors:  Jillian L Scavone; Robert C Sterling; Stephen P Weinstein; Elisabeth J Van Bockstaele
Journal:  Am J Addict       Date:  2013 Jul-Aug

3.  Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire.

Authors:  Antonio D'Amore; Filomena Romano; Vincenzo Biancolillo; Guglielmo Lauro; Ciro Armenante; Anna Pizzirusso; Salvatore Del Tufo; Ciro Ruoppolo; Francesco Auriemma; Francesco Cassese; Patrizia Oliva; Patrizia Amato
Journal:  Clin Drug Investig       Date:  2012-07-01       Impact factor: 2.859

4.  An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Authors:  Richard C Crist; Toni-Kim Clarke; Alfonso Ang; Lisa M Ambrose-Lanci; Falk W Lohoff; Andrew J Saxon; Walter Ling; Maureen P Hillhouse; R Douglas Bruce; George Woody; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

Review 5.  Pharmacotherapy of Opioid Addiction: "Putting a Real Face on a False Demon".

Authors:  E Salsitz; T Wiegand
Journal:  J Med Toxicol       Date:  2016-03

6.  Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.

Authors:  Célian Bertin; Jessica Delorme; Marie Riquelme; Hélène Peyrière; Georges Brousse; Alain Eschalier; Denis Ardid; Chouki Chenaf; Nicolas Authier
Journal:  Br J Clin Pharmacol       Date:  2019-08-24       Impact factor: 4.335

7.  Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.

Authors:  Todd Molfenter; Carol Sherbeck; Mark Zehner; Andy Quanbeck; Dennis McCarty; Jee-Seon Kim; Sandy Starr
Journal:  Subst Abuse Treat Prev Policy       Date:  2015-03-28

8.  Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.

Authors:  T-K Clarke; R C Crist; A Ang; L M Ambrose-Lanci; F W Lohoff; A J Saxon; W Ling; M P Hillhouse; R D Bruce; G Woody; W H Berrettini
Journal:  Pharmacogenomics J       Date:  2013-10-15       Impact factor: 3.550

9.  Improvement of quality of life following 6 months of methadone maintenance therapy in Malaysia.

Authors:  Nizam Baharom; Mohd Rohaizat Hassan; Norsiah Ali; Shamsul Azhar Shah
Journal:  Subst Abuse Treat Prev Policy       Date:  2012-08-01

Review 10.  Naltrexone extended-release injection: an option for the management of opioid abuse.

Authors:  Robert Taylor; Robert B Raffa; Joseph V Pergolizzi
Journal:  Subst Abuse Rehabil       Date:  2011-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.